Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference

Company Overview - Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for cancer, specifically targeting clinically proven kinase targets [3] - The company leverages expertise in chemistry and structure-based drug design to develop innovative small molecules aimed at overcoming resistance and minimizing adverse events [3] - Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, along with multiple discovery-stage research programs [3] Upcoming Events - James Porter, Ph.D., CEO, and Alexandra Balcom, CFO, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on June 5, 2024, at 4:30 p.m. ET in NYC [1] - A live webcast of the event will be available on the company's website and archived for 30 days following the presentation [2]